Sustained activation of TGF-β/Smad3 signaling has been detected in the skin fibroblasts of a bleomycin-induced SSc model, one of the most popular SSc models [10], and targeted disruption of this pathway inhibits bleomycin-induced skin fibrosis [11]. The gene discussed is TGFB1; the disease is systemic sclerosis.